PrediCare

简体中文

Current Standard of Care

Nowadays, the standard-of-care (SOC) treatment options of advanced stage (IIb and IV) solid cancers (e.g., lung, breast , colon cancer) include different therapeutic options, ranging from standard chemotherapies to novel targeted therapeutics or immunotherapies.

READ MORE
The PrediCare Product

PrediCare^TM is a novel software-based treatment navigation tool, predicting the patient’s disease progression moment. This moment is critical in the patient’s therapeutic timeline, being the key factor controlling the change of the treatment plan. PrediCare is designed to be applied in the individual patient treatment, after each current tumor assessment, and prior to the next scheduled tumor assessment.

READ MORE
Optimizing Treatment Switch

PrediCare^TM enables a treatment line switch just prior to an imminent disease progression. This policy adheres to the National Comprehensive Cancer Network (NCCN) guideline, e.g., for switch maintenance therapy in non-small cell lung cancer, but in contrast to the latter modality, PrediCare^TM allows optimization of the timing of the switch in the treatment line, and thus contributes to better patient outcomes.

READ MORE
Technology

The technology of PrediCare^TM relies on an algorithm, which integrates patient level clinical information with a newly-developed machine-learning methodology, which enables extraction and amplification of signals for a forthcoming progression event, from changes in the biomarker dynamics.

READ MORE